Talk about your daily plays, ideas and strategies that do not warrant an actual post. This is the place to request buy/sell advice from the community. Remember to keep it civil. Trade responsibly.
If you're familiar with the microcap space lately, you know 95% of these stocks are speculative, cash-burning, and vehicles of constant dilution. But Heidmar ($HMR) just dropped a Q1 2026 earnings report that shows that solid fundamentals and discipline can …
Hi all, I'm no expert nor do I have much experience doing this sort of thing, but here's why I recently bought some shares in TSXV: HEVI (Helium Evolution). I'd appreciate some feedback on what you all think. **The case …
Ticker: MILI.CN / MILIF Category: Mining / Antimony I rarely find people talking about this stock, so I wanted to bring up a discussion regarding the massive drop yesterday following the Slovakian government’s abrupt cancellation of their exploration license over …
I've been digging into HUBC (HUB Cyber Security) and think it deserves a closer look from investors who follow high-risk, high-reward turnaround and squeeze candidates. A few things that stand out: • Cybersecurity sector exposure with focus on secure data …
$OLB is currently trading around $0.49, near multi-year lows with a market cap under $7M. The company has been making some meaningful moves lately: • Strategic pivot to AI-Driven OmniCommerce • Global PayPal partnership announced earlier this year • Significant …
Been looking at RXRX again and I think it’s one of the cleaner “AI application” plays if money starts rotating out of pure AI hardware / semis and into companies actually using AI in a vertical with proprietary data. Not …
$PRFX had the big after-hours spike. Meanwhile $GLMD has been grinding higher the last couple sessions and is now sitting around $0.71. Quick technical thoughts on $GLMD if it breaks from here: • Currently hovering just above the $0.68–$0.70 area …
Black Diamond Therapeutics recently reported positive Phase 2 data for **silevertinib**, its brain-penetrant EGFR inhibitor for frontline NSCLC patients with **EGFR non-classical mutations**. High-level results from the May update: * **Preliminary median PFS: 15.2 months** * **Median DOR not reached** …
# Top Losers (Biggest Losers) |Rank|Ticker|% Change|Price|Volume|Why / Notes| |:-|:-|:-|:-|:-|:-| |1|**ZCMD**|**-65.14%**|$0.54|\~2M|Sharp drop, possibly post-rally profit taking or bad news.| |2|**SUGP**|**-44.09%**|$1.49|\~2.2M|Heavy selling pressure.| |3|**PLAB**|**-36.42%**|$34.02|10.5M|Significant decline on higher volume (more established company).| |4|**AMSS**|**-25.44%**|$4.25|\~900K|Continuation of weakness.| |5|**HDRN**|**-24.75%**|$3.01|\~500K|Down sharply.| Other losers: **PNRG** (-23.89%), **WCT**, …